Opus Genetics Secures $155 Million Financing

Opus Genetics has successfully secured $155 million in financing from Oberland Capital, bolstering its position in the gene therapy sector. This significant funding will support the company's ongoing development of treatments for inherited retinal diseases. The investment underscores confidence in Opus Genetics' scientific approach and its potential to address unmet medical needs. This financial infusion is expected to accelerate pipeline advancements and solidify the company's leadership in a critical area of biotechnology.